Compound hub · MOTS-c
What is MOTS-c?
MOTS-c is a peptide of 16 amino acids. It is encoded in the mitochondrial genome, inside the gene for 12S ribosomal RNA. Lee and colleagues first reported it in Cell Metabolism in 2015. It is classed as a mitochondrial-derived peptide. Human work on MOTS-c itself in the sources searched is limited to three kinds: measurements of the body's own MOTS-c, genetic association studies and one registered trial that has not reported results.
Stand up from your chair and your muscles start to burn fuel. The power plants doing the burning are your mitochondria. They talk to the rest of the cell the whole time. Researchers now know that part of that talk is written in peptides. The mitochondria's own DNA encodes these peptides. MOTS-c is one of them. It is the subject of the MOTS-c hub.
This page answers the plain questions first. What is MOTS-c? What does the name mean? Is it a peptide? What have studies found? It also answers questions people ask in everyday words, such as whether it affects hunger or the liver. The answers use only what studies measured.
Key facts
| Common name | MOTS-c |
|---|---|
| Full name | Mitochondrial open reading frame of the 12S rRNA type-c |
| Length | 16 amino acids (Lee et al., 2015) |
| Encoded in | Mitochondrial DNA, within the 12S rRNA gene (MT-RNR1) |
| Sequence | MRWQEMGYIFYPRKLR (FDA briefing document, 11 May 2026) |
| Class | Mitochondrial-derived peptide (MDP) |
| First reported | Lee et al., Cell Metabolism, 2015 |
| Natural variant | K14Q (m.1382A>C), a variant specific to Northeast Asian populations (Fuku et al., 2015) |
| Human trial of an analogue | CB4211, NCT03998514, Phase 1a/1b, 2018 to 2021 |
| Registered trial of MOTS-c | NCT07505745, Phase 2a, recruiting, no results posted (ClinicalTrials.gov, 14 October 2026) |
| Sport status | Named as an example of AMPK activators under metabolic modulators in the WADA 2026 Prohibited List, in force from 1 January 2026 |
What is MOTS-c?
MOTS-c is a peptide of 16 amino acids. It is built from a short open reading frame (a stretch of DNA that can be read to make a peptide) inside the gene for 12S ribosomal RNA in mitochondrial DNA. Lee and colleagues found it by searching the human 12S rRNA for small reading frames. They spotted a 51-base-pair candidate with a strong Kozak sequence (the signal that starts translation). This was a computer screen of the human sequence. It is not evidence of clinical effects. They then tested the peptide in cultured cells and mice (Lee et al., Cell Metabolism, 2015).
The mitochondrial origin makes MOTS-c unusual. Your nuclear DNA writes most of the proteins in your mitochondria, and they are shipped in. The mitochondria's own small genome writes MOTS-c. The authors also checked whether the sequence might be a stray copy from the nuclear genome. In a computer comparison of candidate human nuclear and mitochondrial sequences, none of the candidate copies matched the mitochondrial sequence fully. Sequence matching alone is not evidence of a clinical effect (Lee et al., 2015).
PubMed, the biomedical library run by the US National Institutes of Health, indexes the 2015 paper. Its full text is free in PubMed Central. The MOTS-c research guide walks through the studies that followed.
What does 'mitochondrial open reading frame of the 12S rRNA' mean?
Each part of the name is an address. Mitochondrial means the instructions sit in the small genome inside mitochondria, not in the cell nucleus. An open reading frame is a stretch of genetic code that can be read to build a peptide or protein. The 12S rRNA is a mitochondrial gene for a ribosomal RNA, a molecule in the cell's protein-making machinery. The 'type-c' label follows the 2015 naming by Lee and colleagues. They describe MOTS-c as a 16-amino-acid peptide within that gene (Lee et al., 2015).
Finding a peptide hidden in a gene for another kind of RNA is a surprise. It is a bit like finding a second message written between the lines of a letter. It also shows how the discovery happened. The authors ran a computer search of the human 12S rRNA for small open reading frames. They did not start from a known protein. Humanin was found earlier and is another peptide of this type. The MOTS-c paper cites it as the reason to look for more (Lee et al., 2015).
Is MOTS-c considered a peptide?
Yes. MOTS-c is a peptide, a short chain of 16 amino acids, and the original paper calls it one (Lee et al., 2015). Later papers also call it a mitochondrial microprotein, which names it by its small size. They call it a mitochondrial-derived peptide, which names it by origin (Kumagai et al., iScience, 2024; Reynolds et al., Nature Communications, 2021). The words are not competing definitions. They answer two different questions: how long is it, and where does it come from.
Where a peptide ends and a protein begins is a convention, not a law of nature. Chains of 16 units sit comfortably on the peptide side. The same question comes up for other compounds. The guide on whether NAD+ is a peptide shows how the answer turns on structure.
What does research show MOTS-c does in the body?
In cells and mice, Lee et al. found that MOTS-c blocks the folate pathway and the purine synthesis (making the building blocks of DNA) tied to it. This switches on AMPK, an enzyme that senses cellular energy. Skeletal muscle was a major target organ in mice. This is a laboratory result. It does not show the same action in people (Lee et al., 2015). Later work used cell lines with little glucose. It reported that MOTS-c moves into the cell nucleus and changes gene activity. This is also a cell-culture result that does not show the same action in people (Kim et al., Cell Metabolism, 2018). In cell-free tests and mouse muscle, Kumagai et al. reported that MOTS-c binds and activates the enzyme CK2. This is a laboratory and mouse result that does not show the same action in people (iScience, 2024).
The table below shows why the setting matters. A cell experiment can show a mechanism. A mouse can show a whole-animal response. Neither can show what a person would feel. The natural K14Q variant adds a clue from people. The Japanese cohorts had 1,241 people for muscle mass, and 4,966 men and 6,890 women for type 2 diabetes. K14Q carriers had a higher rate of low muscle mass, a marker of sarcopenia (age-related muscle loss), and of type 2 diabetes in men in their 60s. But the rate of diabetes was lower in women in their 50s. The links differed by sex. They did not test supplied MOTS-c (Kumagai et al., 2024).
Does the human body make MOTS-c, and does it change with exercise?
Studies have measured MOTS-c made by the body in human muscle and blood. In one study, 10 sedentary healthy young men exercised on a stationary bicycle. Muscle MOTS-c rose about 12-fold after exercise. Circulating MOTS-c rose about 1.6-fold during exercise and 1.5-fold after it. Then it returned to baseline after four hours of rest. Muscle levels were still high at that mark. This is one small group measured for the body's own peptide (Reynolds et al., Nature Communications, 2021). Another study compared 26 young, 26 middle-aged and 26 older healthy men. Circulating MOTS-c fell with age. Muscle MOTS-c was about 1.5-fold higher in middle-aged and older men than in young men. This again measured the natural peptide in one cohort (D'Souza et al., Aging, 2020).
Measurements like these show that the body has its own MOTS-c signal and that it moves with circumstances. They do not show what happens when MOTS-c comes from outside. That is a different experiment. A 2018 case-control study in China compared 40 obese children and adolescents with 57 controls. Circulating MOTS-c was lower in the obese group. This was seen in males and not in females. In males it went with markers of insulin resistance. This is an association in one small study. It is not a cause (Du et al., Pediatric Diabetes, 2018).
What do studies show about MOTS-c and appetite?
No human study measuring appetite after exposure to MOTS-c was found in the sources searched. Male mice on a normal diet were treated for four days. They showed modest drops in food intake, body weight and blood glucose (Lee et al., 2015). Mice on a high-fat diet ate the same calories whether treated or not (Lee et al., 2015). Old mice treated from late life ate less in total than untreated mice, and their body weight stayed about the same (Reynolds et al., 2021). These mouse findings do not show appetite or weight effects in people. The analogue CB4211 is a different molecule. The sponsor reported a trend toward lower body weight after four weeks in 20 adults with fatty liver disease (11 on CB4211, 9 on placebo). That came from a company press release. It is not a peer-reviewed paper (CohBar press release, 10 August 2021).
The mouse papers recorded how much food the mice ate. That is a weight of pellets. It does not show whether the animals felt hungry. That is a different measurement. No human measurement of appetite after MOTS-c exposure was found in the sources searched for this page on 14 October 2026.
What do studies show about MOTS-c and the liver?
No study of MOTS-c in the human liver was found in the sources searched. In mice with bone cancer, long-term MOTS-c treatment had little effect on liver, renal, lipid or cardiac function. This mouse result does not show human safety (Yang et al., Acta Biochimica et Biophysica Sinica, 2024). In mice on a high-fat diet, MOTS-c treatment cut liver fat build-up (Lee et al., 2015). In mice fed a diet that causes fatty-liver disease with inflammation (NASH), MOTS-c treatment eased liver steatosis (fat build-up), cell death, inflammation and fibrosis (scarring) (Lu et al., Cell Reports, 2024). These two mouse results do not show human liver effects. The analogue CB4211 is a different molecule. In its trial, the sponsor reported larger falls in ALT and AST than on placebo. These are two blood markers of liver injury. The trial had 11 adults with fatty liver disease on CB4211 and 9 on placebo, over four weeks. This is an exploratory result in a company press release. It is not a peer-reviewed paper (CohBar press release, 10 August 2021).
The trial result came from exploratory outcomes in 20 people. The registry lists no results (ClinicalTrials.gov NCT03998514). The registry also shows that people in the first two parts had to start with normal liver enzymes. The fatty-liver part set limits on how high their enzymes could be. The FDA states that it has not identified any human exposure data on drug products containing MOTS-c (FDA page, content current as of 22 April 2026). That leaves the human liver question for MOTS-c itself open.
Which groups has MOTS-c research left out?
Two registered human trials, one of the analogue CB4211 and one of MOTS-c, each set exclusions. The registry record of the analogue trial (ClinicalTrials.gov NCT03998514) lists adults aged 18 to 60. It lists women only if they could not become pregnant. For its first two parts it excludes significant kidney or liver disorders, heart-rhythm abnormalities, active infection and positive hepatitis or HIV tests. The registry record of the MOTS-c trial (NCT07505745) lists adults aged 18 to 65 with prediabetes and a body mass index of 27 to 40. It excludes diabetes, pregnancy, breastfeeding, active cancer needing treatment and clinically significant liver, kidney or cardiovascular disease. Safety data for the excluded groups were not found in the sources searched.
A trial's exclusion list records who researchers chose not to enrol. It is a map of missing data. It is not a safety finding about those groups. Athletes are a separate case. The WADA 2026 Prohibited List, in force from 1 January 2026, names MOTS-c as an example of AMPK activators in its metabolic-modulator class. The doping-control laboratory of the German Sport University Cologne repeats that entry (page last updated 1 June 2026). This is a sport-rule record. It is not a safety finding. The MOTS-c in Perth page covers the sport and Australian listings.
Evidence limits
How strong is the evidence for MOTS-c, and what do online reports add?
The evidence for MOTS-c sits mostly on the lowest rungs of the ladder. The sources searched hold many cell and mouse experiments, human measurements of the body's own MOTS-c, genetic association studies and one finished Phase 1 trial of an analogue. A PubMed search for MOTS-c clinical trial on 14 October 2026 returned five records. Their titles and abstracts describe measurements of natural MOTS-c. They do not describe MOTS-c given to participants. Online posts are individual accounts. They are not controlled studies. A 2026 narrative review of peptide therapies in sports medicine discusses the placebo effect as something that shapes how well peptides seem to work, and how social media amplifies it (Mendias and Awan, Sports Medicine, 2026).
Evidence can show how much weight a claim deserves. For MOTS-c, the human weight is light. The MOTS-c side-effects page sets out the safety record. The quality and verification hub explains how research material is documented. The site catalogue lists MOTS-c reference material as a laboratory reference. It is not a medicine and not for human or animal use.
Comparison
What each kind of MOTS-c evidence can show about people. The examples are named studies from this page. This is a record of evidence types, not a ranking of products or outcomes.
| Evidence type | Example | What it can show | What it cannot show |
|---|---|---|---|
| Cultured cells | Lee et al., 2015; Kim et al., 2018 (cell lines) | A way one cell type works: AMPK activation (Lee et al., 2015) or movement into the nucleus when glucose is limited (Kim et al., 2018). These cell-culture results do not show human responses | How a whole person responds |
| Mice | Lee et al., 2015 (obesity prevented in treated high-fat-fed mice); Reynolds et al., 2021 (better physical performance in treated mice); Kumagai et al., 2024 (CK2 activation in mouse muscle). None of these shows the same response in people | A whole-animal response under set conditions | That the same response occurs in people |
| Human measurements of natural MOTS-c | Reynolds et al., 2021 (10 sedentary young men); D'Souza et al., 2020 (26 men in each of three age groups) | In 10 sedentary young men, the body's own MOTS-c rose with exercise (Reynolds et al., 2021). In 26 healthy men in each of three age groups, circulating MOTS-c fell with age (D'Souza et al., 2020). Both small studies measured the body's own peptide. Neither tested supplied MOTS-c | What supplied MOTS-c does |
| Human genetic association | Kumagai et al., 2024 (K14Q variant; Japanese cohorts of 1,241 people for muscle mass, 4,966 men and 6,890 women for type 2 diabetes) | In Japanese cohorts of 1,241 people for muscle mass, 4,966 men and 6,890 women for type 2 diabetes, K14Q carriers had a higher rate of low muscle mass and of diabetes in men in their 60s, but a lower diabetes rate in women in their 50s. These links differ by sex. They did not test supplied MOTS-c (Kumagai et al., 2024) | A test of supplied MOTS-c |
| Human trial of an analogue | CB4211, NCT03998514 (88 participants; company report of 29 March 2022) | In the CB4211 analogue trial (88 enrolled per registry; healthy adults and adults with fatty liver disease), the sponsor reported no serious adverse events. Only the sponsor reports this. The registry has no results posted. It does not establish MOTS-c safety (CohBar annual report, 29 March 2022) | Safety or results for MOTS-c itself |
FAQ
Have studies reported how people feel after MOTS-c?
No published study reporting how people feel after receiving MOTS-c was found in the sources searched. The analogue trial had a four-week Phase 1b stage with 20 adults with fatty liver disease. The sponsor reported that the only adverse events in more than 10% of participants were short reactions at the site where the drug was given. They were rated mild to moderate. The study had no serious adverse events. This is a company press release about a different molecule (CohBar press release, 10 August 2021). Personal accounts online are not controlled studies.
How long does MOTS-c stay raised after exercise?
In 10 sedentary healthy young men, circulating MOTS-c rose during exercise. It returned to baseline after four hours of rest. Muscle levels were still high at that point. This describes the body's own peptide in one small group. It does not describe a supplied one (Reynolds et al., Nature Communications, 2021).
What is the K14Q variant of MOTS-c?
K14Q is a natural change at position 14 of MOTS-c. In lab binding work, Kumagai et al. reported that K14Q MOTS-c bound less to the enzyme CK2. This does not show effects of supplied MOTS-c in humans (iScience, 2024). K14Q is tied to the m.1382A>C mitochondrial variant. Fuku et al. suggested that this variant may be among the possible reasons for the long lifespan of Japanese people. This is a hypothesis, not a finding (Aging Cell, 2015).
Is MOTS-c the same thing as CB4211?
The sponsor of CB4211 described it as a novel and improved analog of MOTS-c (CohBar annual report, 29 March 2022). It was tested in a Phase 1a/1b trial (ClinicalTrials.gov NCT03998514). An analogue is a related molecule with a modified structure. Its results are not results for MOTS-c itself.
More in this hub
Citations
10 sourcesLee C, Zeng J, Drew BG, et al. Cell Metabolism. 2015;21(3):443-454.
doi:10.1016/j.cmet.2015.02.009Kim KH, Son JM, Benayoun BA, Lee C Cell Metabolism. 2018;28(3):516-524.e7.
doi:10.1016/j.cmet.2018.06.008Reynolds JC, Lai RW, Woodhead JST, et al. Nature Communications. 2021;12(1):470.
doi:10.1038/s41467-020-20790-0Kumagai H, Kim SJ, Miller B, et al. iScience. 2024;27(11):111212.
doi:10.1016/j.isci.2024.111212D'Souza RF, Woodhead JST, Hedges CP, et al. Aging. 2020;12(6):5244-5258.
doi:10.18632/aging.102944Du C, Zhang C, Wu W, et al. Pediatric Diabetes. 2018.
doi:10.1111/pedi.12685Yang L, Li M, Liu Y, et al. Acta Biochimica et Biophysica Sinica. 2024;56(9):1323-1339.
doi:10.3724/abbs.2024048Lu H, Fan L, Zhang W, et al. Cell Reports. 2024;43(1):113587.
doi:10.1016/j.celrep.2023.113587Fuku N, Pareja-Galeano H, Zempo H, et al. Aging Cell. 2015;14(6):921-923.
doi:10.1111/acel.12389Mendias CL, Awan TM Sports Medicine. 2026;56(8):1921-1935.
doi:10.1007/s40279-026-02437-0
Continue
MOTS-c reference materialResearch use only: not for human or animal use.
Read the MOTS-c research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
